Corticotrophin and tetracosactrin depot–self-administered for the treatment of eczema
- 1 March 1976
- journal article
- Published by Wiley in British Journal of Dermatology
- Vol. 94 (s12) , 135-138
- https://doi.org/10.1111/j.1365-2133.1976.tb02284.x
Abstract
The prolonged use of self-administered corticotrophin in the form of 'CMC ACTH' (Crookes) or 'Synacthen Depot' (Ciba) has been considered in twenty-seven patients with severe subactute of chronic eczema. Complications were not troublesome and the therapeutic response was good. Many of the patients were able to control their disease fully without the effort and discomfort of additional local treatment and patients' acceptance of the treatment was high.Keywords
This publication has 6 references indexed in Scilit:
- Indirect Estimation of Pituitary Corticotropin Reserve in Man by Use of an Adrenocortical 11 β-hydroxylase Inhibitor (SU-4885 Ciba)Acta Medica Scandinavica, 2009
- PITUITARY-ADRENAL RESPONSE TO SURGICAL STRESS IN PATIENTS RECEIVING CORTICOTROPHIN TREATMENTThe Lancet, 1970
- Effect of corticotrophin therapy on pituitary-adrenal function.Annals of the Rheumatic Diseases, 1970
- Hypothalamo-pituitary-adrenal function in patients on long-term adrenocorticotrophin therapy.Annals of the Rheumatic Diseases, 1968
- EFFECT OF LONG-TERM CORTICOSTEROIDS AND CORTICOTROPHIN ON THE GROWTH OF CHILDRENThe Lancet, 1966
- Suppression of the Pituitary-ACTH Response In Man By Administration of ACTH or Cortisol*†Journal of Clinical Endocrinology & Metabolism, 1962